key: cord-0710205-fbmk9479
authors: de Chaisemartin, Luc; Diep, Antoine; Gonnin, Cécile; Soria, Angèle; Barbaud, Annick; Nicaise-Roland, Pascale
title: Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines: Not the usual suspects?
date: 2022-02-22
journal: Ann Allergy Asthma Immunol
DOI: 10.1016/j.anai.2021.11.012
sha: c1d53d4982795184ef763f821e46df4d8f936575
doc_id: 710205
cord_uid: fbmk9479

nan

Immune parameters during anaphylaxis to messenger RNA coronavirus disease 2019 vaccines Not the usual suspects?

Soon after the release of the new anti−coronavirus disease 2019 messenger RNA vaccines, reports of anaphylactic reactions came in from the United States. [1] [2] [3] Cases were reported for both Pfizer BNT162b2 and Moderna mRNA-1273 vaccines with an estimated frequency of 4.7 and 2.5 cases per million doses, respectively. 3 Allergic reactions to vaccines are rare and mostly due to vaccine excipients. 4 Therefore, the polyethylene glycol present in both mRNA formulations was soon suspected to be the culprit. 5 Several hypersensitivity mechanisms to polyethylene glycol have been described, such as classical immunoglobulin E (IgE)−dependent anaphylaxis and complement activation-related pseudoallergy. 6 In their interesting work, Kohli-Pamnani et al 7 conclude to the absence of an IgE-mediated mechanism in 39 individuals, based on negative skin testing and negative serum mast cell tryptase results. In addition, they did not confirm a complement activation-related pseudoallergy syndrome owing to normal sC5b9 levels in an undisclosed number of individuals. To expand on these findings, we explored in more detail putative immunologic mechanisms in patients presenting with COVID-19 anaphylaxis.

As a reference clinical laboratory for anaphylaxis in Paris, France, we collected samples from 5 patients suspected of having anaphylaxis from more than 208,000 people who were vaccinated in Paris hospitals during this period. All received the BNT162b2 vaccine.

We received a sample within 2 hours of the reaction for all patients, an early (<30 minutes) sample for 4 of 5 patients and a late (basal) sample for 2 of 5 patients.

All patients had normal tryptase levels for all time points. In addition, histamine levels were normal in all patients but one at the first time point. Interestingly, histamine levels normalized in the second sample in this patient, suggesting that histaminoliberation could be involved. We also measured levels of C5a and soluble C5b9 complexes in the blood. These levels did not change over time nor substantially differed from basal levels of unvaccinated healthy controls (n=18). Finally, we previously described in neuromuscular blocking agent anaphylaxis an IgG-dependent mechanism with neutrophil activation. 8 Accordingly, we measured neutrophil elastase plasma levels and found them comparable with those of healthy controls. Finally, using mass spectrometry, we measured leukotrienes (B4, B5) and prostaglandins (D2, E2, F2) but did not find marked difference with normal plasma levels.

All in all, we did not find any sign of immune system activation in these patients at the time of the reaction except for one case of histamine release. More importantly, 3 of 5 patients could be revaccinated with the same mRNA vaccine (patient 1 had already received both doses and patient 4 died of unrelated cause before his second dose). Consistently with the data of Kohli-Pamnani et al, 7 all re-exposures went without any incident.

In summary, we found that COVID-19 mRNA vaccine anaphylaxis does not seem to rely on an IgE-, IgG-, or complement-mediated mechanism. Even nonspecific histamine liberation does not seem to be frequent because it was present in only 1 patient. Although more work is needed to understand the exact nature of the mechanism behind the symptoms, it seems safe, based on the available evidence for Kohli-Pamnani et al 7 and ours, to recommend vaccine reintroduction under antihistamine premedication. the suggestion that antihistamine premedication may prevent some allergic reactions. 3 Most patients will tolerate subsequent vaccination with the mRNA COVID-19 vaccine with or without premedication. [1] [2] [3] [4] [5] [6] [7] In the report of de Chaisemartin et al, 1 3 of 5 patients tolerated their consequent COVID-19 mRNA vaccine. Furthermore, 1 patient already received their second dose to which anaphylaxis had occurred. In addition, 1 patient passed away from unrelated cause before the receipt of vaccine dose 2. In our case series, 95% (n = 37) tolerated their succeeding COVID-19 vaccine without serious allergic reaction. Moreover, 92% (n = 36) received 2 doses of their COVID-19 vaccines. Of the patients who tolerated their subsequent mRNA vaccines, 62% received premedication, which could include H 1 and H 2 antihistamines and leukotriene inhibitors.

A potential explanation of transiently elevated serum histamine levels in the patient described by de Chaisemartin et al 1 could be basophil activation. Warren et al 8 revealed that 11 patients with anaphylactic reactions to the COVID-19 mRNA vaccine had negative skin test results to the vaccine and excipients. Nevertheless, most had positive basophil activation test results to PEG. All had positive basophil activation test results to the mRNA vaccine. Notably, PEG immunoglobulin G was found despite undetectable PEG immunoglobulin E in the tested patients with allergic reactions.

In summary, de Chaisemartin et al 1 raise an interesting point on possible transient elevation of serum histamine levels. Further research is necessary to characterize skin tests with the specific vaccines and biomarkers such as serum histamine levels to evaluate which endotypes of post−COVID-19 mRNA vaccine allergic reactions may benefit from premedication or desensitization to COVID-19 mRNA vaccines.

Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine -United States

First month of COVID-19 vaccine safety monitoring-United States

Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US

Immune parameters during anaphylaxis to mRNA COVID-19 vaccines: not the usual suspects?

Coronavirus disease 2019 vaccine hypersensitivity evaluated with vaccine and excipient allergy skin testing

Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don't give up on the second dose! Allergy

Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose

First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing

Allergic reactions to coronavirus disease 2019 vaccines and addressing vaccine hesitancy: Northwell Health experience

Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination

Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US regional health system